Keith Durkin1, Nicolas Rosewick1,2, Maria Artesi1, Vincent Hahaut1, Philip Griebel3,4, Natasa Arsic3, Arsène Burny2, Michel Georges1, Anne Van den Broeke5,6. 1. Unit of Animal Genomics, GIGA-R, Université de Liège (ULg), 4000, Liège, Belgium. 2. Laboratory of Experimental Hematology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), 1000, Brussels, Belgium. 3. Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, S7N 2Z4, Canada. 4. School of Public Health, University of Saskatchewan, Saskatoon, S7N 2Z4, Canada. 5. Unit of Animal Genomics, GIGA-R, Université de Liège (ULg), 4000, Liège, Belgium. anne.vandenbroeke@bordet.be. 6. Laboratory of Experimental Hematology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), 1000, Brussels, Belgium. anne.vandenbroeke@bordet.be.
Abstract
BACKGROUND: Bovine Leukemia Virus (BLV) is a deltaretrovirus closely related to the Human T cell leukemia virus-1 (HTLV-1). Cattle are the natural host of BLV where it integrates into B-cells, producing a lifelong infection. Most infected animals remain asymptomatic but following a protracted latency period about 5 % develop an aggressive leukemia/lymphoma, mirroring the disease trajectory of HTLV-1. The mechanisms by which these viruses provoke cellular transformation remain opaque. In both viruses little or no transcription is observed from the 5'LTR in tumors, however the proviruses are not transcriptionally silent. In the case of BLV a cluster of RNA polymerase III transcribed microRNAs are highly expressed, while the HTLV-1 antisense transcript HBZ is consistently found in all tumors examined. RESULTS: Here, using RNA-seq, we demonstrate that the BLV provirus also constitutively expresses antisense transcripts in all leukemic and asymptomatic samples examined. The first transcript (AS1) can be alternately polyadenylated, generating a transcript of ~600 bp (AS1-S) and a less abundant transcript of ~2200 bp (AS1-L). Alternative splicing creates a second transcript of ~400 bp (AS2). The coding potential of AS1-S/L is ambiguous, with a small open reading frame of 264 bp, however the transcripts are primarily retained in the nucleus, hinting at a lncRNA-like role. The AS1-L transcript overlaps the BLV microRNAs and using high throughput sequencing of RNA-ligase-mediated (RLM) 5'RACE, we show that the RNA-induced silencing complex (RISC) cleaves AS1-L. Furthermore, experiments using altered BLV proviruses with the microRNAs either deleted or inverted point to additional transcriptional interference between the two viral RNA species. CONCLUSIONS: The identification of novel viral antisense transcripts shows the BLV provirus to be far from silent in tumors. Furthermore, the consistent expression of these transcripts in both leukemic and nonmalignant clones points to a vital role in the life cycle of the virus and its tumorigenic potential. Additionally, the cleavage of the AS1-L transcript by the BLV encoded microRNAs and the transcriptional interference between the two viral RNA species suggest a shared role in the regulation of BLV.
BACKGROUND:Bovine Leukemia Virus (BLV) is a deltaretrovirus closely related to the Human T cell leukemia virus-1 (HTLV-1). Cattle are the natural host of BLV where it integrates into B-cells, producing a lifelong infection. Most infected animals remain asymptomatic but following a protracted latency period about 5 % develop an aggressive leukemia/lymphoma, mirroring the disease trajectory of HTLV-1. The mechanisms by which these viruses provoke cellular transformation remain opaque. In both viruses little or no transcription is observed from the 5'LTR in tumors, however the proviruses are not transcriptionally silent. In the case of BLV a cluster of RNA polymerase III transcribed microRNAs are highly expressed, while the HTLV-1 antisense transcript HBZ is consistently found in all tumors examined. RESULTS: Here, using RNA-seq, we demonstrate that the BLV provirus also constitutively expresses antisense transcripts in all leukemic and asymptomatic samples examined. The first transcript (AS1) can be alternately polyadenylated, generating a transcript of ~600 bp (AS1-S) and a less abundant transcript of ~2200 bp (AS1-L). Alternative splicing creates a second transcript of ~400 bp (AS2). The coding potential of AS1-S/L is ambiguous, with a small open reading frame of 264 bp, however the transcripts are primarily retained in the nucleus, hinting at a lncRNA-like role. The AS1-L transcript overlaps the BLV microRNAs and using high throughput sequencing of RNA-ligase-mediated (RLM) 5'RACE, we show that the RNA-induced silencing complex (RISC) cleaves AS1-L. Furthermore, experiments using altered BLV proviruses with the microRNAs either deleted or inverted point to additional transcriptional interference between the two viral RNA species. CONCLUSIONS: The identification of novel viral antisense transcripts shows the BLV provirus to be far from silent in tumors. Furthermore, the consistent expression of these transcripts in both leukemic and nonmalignant clones points to a vital role in the life cycle of the virus and its tumorigenic potential. Additionally, the cleavage of the AS1-L transcript by the BLV encoded microRNAs and the transcriptional interference between the two viral RNA species suggest a shared role in the regulation of BLV.
Authors: A Van Den Broeke; C Bagnis; M Ciesiolka; Y Cleuter; H Gelderblom; P Kerkhofs; P Griebel; P Mannoni; A Burny Journal: J Virol Date: 1999-02 Impact factor: 5.103
Authors: C A Stein; J Bo Hansen; Johnathan Lai; SiJian Wu; Anatoliy Voskresenskiy; Anja Høg; Jesper Worm; Maj Hedtjärn; Naira Souleimanian; Paul Miller; Harris S Soifer; Daniella Castanotto; Luba Benimetskaya; Henrik Ørum; Troels Koch Journal: Nucleic Acids Res Date: 2009-10-23 Impact factor: 16.971
Authors: Lucy B M Cook; Anat Melamed; Maria Antonietta Demontis; Daniel J Laydon; James M Fox; Jennifer H C Tosswill; Declan de Freitas; Ashley D Price; James F Medcalf; Fabiola Martin; James M Neuberger; Charles R M Bangham; Graham P Taylor Journal: Retrovirology Date: 2016-01-08 Impact factor: 4.602
Authors: María L De Brun; Bruno Cosme; Marcos Petersen; Irene Alvarez; Aurea Folgueras-Flatschart; Roberto Flatschart; Carlos Javier Panei; Rodrigo Puentes Journal: J Vet Diagn Invest Date: 2022-04-02 Impact factor: 1.569
Authors: Nicolas Rosewick; Keith Durkin; Maria Artesi; Ambroise Marçais; Vincent Hahaut; Philip Griebel; Natasa Arsic; Véronique Avettand-Fenoel; Arsène Burny; Carole Charlier; Olivier Hermine; Michel Georges; Anne Van den Broeke Journal: Nat Commun Date: 2017-05-23 Impact factor: 14.919
Authors: Anton I Petrov; Simon J E Kay; Ioanna Kalvari; Kevin L Howe; Kristian A Gray; Elspeth A Bruford; Paul J Kersey; Guy Cochrane; Robert D Finn; Alex Bateman; Ana Kozomara; Sam Griffiths-Jones; Adam Frankish; Christian W Zwieb; Britney Y Lau; Kelly P Williams; Patricia P Chan; Todd M Lowe; Jamie J Cannone; Robin Gutell; Magdalena A Machnicka; Janusz M Bujnicki; Maki Yoshihama; Naoya Kenmochi; Benli Chai; James R Cole; Maciej Szymanski; Wojciech M Karlowski; Valerie Wood; Eva Huala; Tanya Z Berardini; Yi Zhao; Runsheng Chen; Weimin Zhu; Maria D Paraskevopoulou; Ioannis S Vlachos; Artemis G Hatzigeorgiou; Lina Ma; Zhang Zhang; Joern Puetz; Peter F Stadler; Daniel McDonald; Siddhartha Basu; Petra Fey; Stacia R Engel; J Michael Cherry; Pieter-Jan Volders; Pieter Mestdagh; Jacek Wower; Michael B Clark; Xiu Cheng Quek; Marcel E Dinger Journal: Nucleic Acids Res Date: 2016-10-28 Impact factor: 19.160